Abrocitinib: The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis
15 Jul 2022
Abrocitinib, the first janus kinase (JAK)1
inhibitor specifically indicated for
the treatment of moderate-to-severe atopic
dermatitis (AD), was recently
approved in Singapore. During a webinar
hosted by the Dermatological
Society of Singapore, with the support of Pfizer,
Professor Stephan Weidinger
of University Hospital Scheswig-Holstein,
Germany discussed several cases
that exemplified appropriate patient selection
for this novel agent.
Resources
Abrocitinib-The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis
Abrocitinib-The Novel Oral Treatment for Moderate-to-Severe Atopic Dermatitis